CA-EXPERIAN
4.4.2022 19:04:05 CEST | Business Wire | Press release
Experian, a global information services company which provides technology, data and analytics to its clients, was named the top established leader in digital identity in Juniper Research’s Digital Identity Competitor Leaderboard . The report provides a five-year forecast for the digital identity sector and cites Experian and its CrossCore™ platform as the market leader in capacity, capability, and product strength.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005775/en/
“We’re thrilled Juniper Research has positioned us as the top provider of digital identity,” said David Britton, Vice President of Global Strategy for Digital Identity & Fraud at Experian. “Being able to accurately identify a customer in a digital transaction helps our clients provide a better customer experience and prevent fraud. Fighting fraud and reducing risk, while enabling great consumer experience, is at the heart of Experian’s mission to make the digital world a safer place, even as cybersecurity rises as a worldwide threat.”
CrossCore, Experian’s flagship digital identity and fraud management platform, was first launched in 2016 and is currently used by over 400 clients worldwide. More recent acquisitions and new third-party partners have expanded CrossCore’s identity and fraud capabilities and expanded its reach. Other Experian Identity & Fraud and Decisioning products are integrated into CrossCore, and customers can connect their own products into the platform as well. Learn more about the CrossCore platform here .
Juniper Research noted CrossCore’s recent updates to further improve identity verification processes and noted, “One of the key advantages of the platform is the flexibility it provides: customers are enabled to specify services needed based on the workflow logic and decision criteria for each transaction. Business customers are also empowered to use self-service workflows and reporting mechanisms, allowing them to adapt their strategies.” Experian was also noted for its high expertise in partnerships, identification coverage, customers and deployments.
About Experian
Experian is the world’s leading global information services company. During life’s big moments — from buying a home or a car to sending a child to college to growing a business by connecting with new customers — we empower consumers and our clients to manage their data with confidence. We help individuals to take financial control and access financial services, businesses to make smarter decisions and thrive, lenders to lend more responsibly, and organizations to prevent identity fraud and crime.
We have 20,000 people operating across 44 countries, and every day we’re investing in new technologies, talented people and innovation to help all our clients maximize every opportunity. We are listed on the London Stock Exchange (EXPN) and are a constituent of the FTSE 100 Index.
Learn more at www.experianplc.com , visit our global insights content hub at our global news blog for the latest news and insights from the Group.
Experian and the Experian trademarks used herein are trademarks or registered trademarks of Experian and its affiliates. Other product and company names mentioned herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005775/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
Credit Derivatives Determinations Committees Membership applications for 202627.3.2026 17:30:00 CET | Press release
DC Administration Services, Inc. (DCAS) would like to invite all interested Members of ISDA to apply for a position as a member of the Credit Derivatives Determinations Committees. There is a separate Determinations Committee for each of the relevant regions. Members of ISDA may apply for membership as either a Dealer Member of the Determinations Committees or a Non-Dealer Member of the Determinations Committees (as applicable). Parties wishing to apply for such a position should carefully review and submit either an executed Dealer Participation Letter (for a prospective Dealer Member) or an executed Non-dealer Committee Participation Letter (for a prospective Non-Dealer Member) by 5pm (New York time) on Friday, April 3, 2026. CCPs may also apply to participate as a CCP Member by submitting a Participating CCP Institution Letter. For more information on the process and to download the form of the relevant letter, please visit https://www.cdsdeterminationscommittees.org/about-dc-commit
Andersen Consulting indgår samarbejdsaftale med Solutia27.3.2026 15:22:00 CET | Pressemeddelelse
Andersen Consulting udvider sin tilstedeværelse i Spanien gennem en samarbejdsaftale med Solutia, en virksomhed med speciale i løsninger inden for arbejdsmiljø og sundhed samt rekruttering inden for life science- og sundhedssektoren. Solutia blev stiftet i 2014 og tilbyder omfattende tjenester og rådgivning med fokus på sunde arbejdsmiljøer, sygefravær, outsourcing af sundhedsydelser og uddannelse til organisationer på tværs af alle sektorer. Virksomheden leverer også rekrutterings- og executive search-løsninger med fokus på life science, tekniske fagfolk samt mellem- og topledelse samt dybdegående ekspertise inden for medicinal-, bioteknologi-, medico- og sundhedsindustrien. Ved hjælp af datadrevne og skræddersyede løsninger hjælper Solutia virksomheder med at optimere medarbejdereffektiviteten og tiltrække specialister. "Vores mål er at forbedre, hvordan organisationer tiltrækker, udvikler og leder medarbejdere i et stadig mere komplekst miljø," udtalte Cesar Castel, administrerende
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
